Amarin Corporation PLC

AMRN Healthcare Drug Manufacturers General

Amarin Corporation PLC’s revenue for fiscal 2025 (year ended December 2025) was $213.6 million, down 6.55% from fiscal 2024. In the quarter to June 2026, revenue fell 42.0%, EPS grew 45.8% and free cash flow fell 60.2%, each against the same quarter a year earlier.

11.37 0.20 −1.73%
Market cap
$244.4M
P/E
0.0×
Fwd P/E
−398×
Dividend yield
—
F-score
7/9
Altman Z
−1.86
Beneish M
−3.26
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(5.97%) (7.28%) (8.21%) (17.41%)

+8 more TTM periods

Piotroski F-Score
6 6 7 4
ROA
(4.19%) (5.17%) (5.72%) (12.22%)
ROIC
(19.79%) (19.78%) (20.04%) (35.02%)
Return on Tangible Assets
(6.18%) (7.53%) (8.52%) (19.32%)
Average Days of Receivables
182.11 181.95 216.68 204.94
Free Cash Flow per Share
0.75 1.22 0.32 (1.05)
Free Cash Flow
15.57 25.58 6.73 (21.86)
Other line items

Show all line items

Columns are period end dates